Direkt zum Inhalt
Merck

L-018

Supelco

Lidocaine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

1 ML
51,70 €

51,70 €


Versandbereit am22. April 2025Details


Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
1 ML
51,70 €

About This Item

Empirische Formel (Hill-System):
C14H22N2O
CAS-Nummer:
Molekulargewicht:
234.34
EG-Nummer:
UNSPSC-Code:
41116107
NACRES:
NA.24

51,70 €


Versandbereit am22. April 2025Details


Bulk-Bestellung anfordern

Qualität

certified reference material

Qualitätsniveau

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

1.0 mg/mL in methanol

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

forensics and toxicology

Format

single component solution

Lagertemp.

−20°C

SMILES String

CCN(CC)CC(=O)Nc1c(C)cccc1C

InChI

1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)

InChIKey

NNJVILVZKWQKPM-UHFFFAOYSA-N

Allgemeine Beschreibung

Lidocaine is a local anesthetic and antiarrhythmic drug. This analytical reference standard is suitable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Lidocaine is often added to cocaine as a diluent.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 1

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup


Zulassungslistungen

Zulassungslistungen werden hauptsächlich für chemische Produkte erstellt. Für nicht-chemische Produkte können hier nur begrenzte Angaben gemacht werden. Kein Eintrag bedeutet, dass keine der Komponenten gelistet ist. Es liegt in der Verantwortung des Benutzers, die sichere und legale Verwendung des Produkts zu gewährleisten.

EU REACH Annex XVII (Restriction List)

CAS No.

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

M Soledad Cepeda et al.
The Cochrane database of systematic reviews, (12)(12), CD006581-CD006581 (2010-12-15)
Lidocaine administration produces pain due to its acidic pH. The objective of this review was to determine if adjusting the pH of lidocaine had any effect on pain resulting from non-intravascular injections in adults and children. We tested the hypothesis
Jason Wasiak et al.
The Cochrane database of systematic reviews, 6(6), CD005622-CD005622 (2012-06-15)
This is an update of the review on 'Lidocaine for pain relief in burn injured patients' first published in Issue 3, 2007. Pain is a major issue for patients suffering from many different types of wounds, in particular those with
Bettina F Cuneo et al.
Circulation, 128(20), 2183-2191 (2013-11-13)
The electrophysiology of long QT syndrome (LQTS) in utero is virtually unstudied. Our goal here was to evaluate the efficacy of fetal magnetocardiography (fMCG) for diagnosis and prognosis of fetuses at risk of LQTS. We reviewed the pre/postnatal medical records
S Picardi et al.
British journal of anaesthesia, 112(2), 370-379 (2013-09-26)
Signalling of several G-protein-coupled receptors of the Gq/11 family is time-dependently inhibited by local anaesthetics (LAs). Since LA-induced modulation of muscarinic m1 and m3 receptor function may explain their beneficial effects in clinical practice, such as decreased postoperative cognitive dysfunction
Paul M A Broens et al.
Diseases of the colon and rectum, 56(11), 1273-1281 (2013-10-10)
None of the current theories on fecal incontinence can explain fecal continence adequately. This study aims to evaluate the mechanism controlling fecal continence. Anal electrosensitivity, anorectal pressures, and rectal pressure volumetry tests were performed in 17 controls before and after

Fragen

Bewertungen

Kein Beurteilungswert

Aktive Filter

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.